Stanford's Atreca floated in the middle of its range and will use the funding to advance its lead cancer immunotherapeutic canadidate through the clinic.

Atreca, a US-based immunotherapeutics developer based on research at Stanford University, has raised approximately $125m in an initial public offering that achieved an exit for pharmaceutical firm GlaxoSmithKline (GSK). The offering consisted of 7.35 million class A shares on the Nasdaq Global Select Market priced at $17.00 each, in the middle of the IPO’s range.…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.